Organizing Committee Office
Division of Gastroenterology,
Department of Medicine,
Kurume University
School of Medicine
67 Asahi-machi, Kurume
830-0011, JAPAN
Conference Secretariat
c/o Convention Linkage, Inc.
Daisan Hakata Kaisei Bldg.,
1-3-6, Hakata-eki-minami,
Hakata-ku, Fukuoka-shi,
Fukuoka, 812-0016, Japan
TEL: +81-92-437-4188
FAX: +81-92-437-4182
E-mail:jshilc2021@c-linkage.co.jp
Program
Scientific Program
Day 1: Saturday, October 2, 2021
[Room 1]
Session I 8:30-10:00
Systemic therapy for HCC (TKI, ICI and others)
- Chair：
- Masafumi Ikeda
National Cancer Center Hospital East, Japan - Sadahisa Ogasawara
Chiba University, Japan - Ann-Lii Cheng
National Taiwan University Cancer Center, Taiwan.
Session Ⅰ-1
Sequential changes in growth factors during lenvatinib
treatment in patients with unresectable hepatocellular carcinoma
- Zijian Yang
Hokkaido University, Sapporo, Japan
Session Ⅰ-2
Progress of systematic therapy for HCC in Asia
- Stephen L. CHAN
The Chinese University of Hong Kong, Hong Kong SAR, China
Session Ⅰ-3
Recent progress of systemic therapy for HCC in Japan
- evidence and clinical practice
- Hiroshi Aikata
Hiroshima University, Japan
Session Ⅰ-4
Advances in Systemic Therapy in HCC
- Richard S. Finn
David Geffen School of Medicine at University of
California Los Angeles, USA
Workshop I 10:05-11:35
Real-world experience of immunotherapy for HCC
- Chair：
- Shuichi Kaneko
Kanazawa University, Japan - Hironori Koga
Kurume University School of Medicine, Japan - Pei-Jer Chen
National Taiwan University Hospital, Taiwan
Workshop I-1
Immunotherapy in HCC
- Bruno Sangro
Clinica Universidad de Navarra, Spain
Workshop I-2
Real-world experience of immunotherapy for HCC in Singapore
- David Tai
National Cancer Centre, Singapore, Singapore
Workshop I-3
Efficacy and risk of HBV reactivation of immune checkpoint inhibitors
treatment for unresectable HCC: real-world experience from Taiwan
- Yi-Hsiang Huang
National Yang Ming Chiao Tung University, Taiwan
Workshop I-4
Initial experiences of atezolizumab combined with bevacizumab in
patients with advanced hepatocellular carcinoma: Retrospective analysis
at five institutions in Japan
- Miyuki Nakagawa
Chiba University, Japan
Symposium I 14:10-17:10
Treatment for BCLC-B
- Chair：
- Tetsuo Takehara
Osaka University, Japan - Tatsuya Yamashita
Kanazawa University, Japan - Riccardo Lencioni
University of Pisa, Italy - Richard S. Finn
University of California Los Angeles, USA
Symposium I-1
Treatment choice for intermediate stage (up-to-7 in) HCC
- Kazuhiro Nouso
Okayama City Hospital, Japan
Symposium I-2
Treatment choice for patients with intermediate stage hepatocellular
carcinoma; a single center retrospective study.
- Noriyo Yamashiki
Kansai Medical University, Japan
Symposium I-3
A new therapeutic strategy for BCLC stage B
～Combination approach with local and systemic therapy to
achieve a loco-regional cure ～
- Kaoru Tsuchiya
Musashino Red Cross Hospital, Japan
Symposium I-4
Treatment of BCLC-B stage hepatocellular carcinoma: Korean
perspectives
- Seung Up Kim
Yonsei University, Korea
Symposium I-5
Systemic treatments in patients with BCLC-B stage hepatocellular
carcinoma
- Atsushi Hiraoka
Ehime Prefectural Central Hospital, Japan
Symposium I-6
Management of BCLC stage B HCC-evolving new strategies
- Andrew X. Zhu
Massachusetts General Hospital, USA
[Room 2]
Session Ⅱ 8:30-10:00
Technical tips for HCC (Surgery/IVR/PRFA/Radiation）
- Chair：
- Namiki Izumi
Musashino Red Cross Hospital, Japan - Mitsuo Shimada
Tokushima University, Japan - Bruno Sangro
Clinica Universidad de Navarra, Spain - Jinsil Seong
Yonsei University, Korea
Session Ⅱ-1
The Changing Face of HCC in the United States: Evolution of
Demographics and Treatment
- Myron Schwartz
Icahn School of Medicine at Mount Sinai, USA
Session Ⅱ-2
Ablation in Japan: SURF trial, new-generation MWA,
ablation with systemic therapy, and ablation webinar
- Shuichiro Shiina
Juntendo University, Japan
Session Ⅱ-3
Advances in transarterial chemoembolization for hepatocellular carcinoma
- Shiro Miyayama
Fukui-ken Saiseikai Hospital, Japan
Session Ⅱ-4
Hepatic arterial infusion chemotherapy (HAIC) for long-term prognosis in
patients with advanced hepatocellular carcinoma involving vascular
invasion
- Hiroaki Nagamatsu
Juntendo University, Japan
Session Ⅲ 10:05-11:35
Surgical therapy (including liver transplantation)
- Chair：
- Susumu Eguchi
Nagasaki University, Japan - Tomoharu Yoshizumi
Kyushu University, Japan - Myron Schwartz
Icahn School of Medicine at Mount Sinai,USA
Session Ⅲ-1
Open hepatectomy for hepatocellular carcinoma in future
- Kiyoshi Hasegawa
The University of Tokyo, Japan
Session Ⅲ-2
Laparoscopic and robotic hepatectomy for hepatocellular carcinoma
- Gi Hong Choi
Yonsei University, Korea
Session Ⅲ-3
Current status of liver transplantation for hepatocellular carcinoma
in Japan
- Toru Ikegami
The Jikei University School of Medicine, Japan
Session Ⅲ-4
Surgical and oncological outcomes of conversion surgery for initially
unresectable locally advanced hepatocellular carcinoma at Kurume
University ~Hepatic arterial infusion chemotherapy with New FP
regimen~
- Yuichi Goto
Kurume University, Japan
Session Ⅳ 14:10-17:10
Basic Research for HCC and CCC
- Chair：
- Hirohisa Yano
Kurume University, Japan - Tatsuya Kanto
National Center for Global Health and Medicine, Japan - Lewis R. Roberts
Mayo Clinic College of Medicine and Science, USA
Session Ⅳ-1
Novel molecular targets of cholangiocarcinoma and their translational
implications for drug development
- Lewis R. Roberts
Mayo Clinic College of Medicine and Science, USA
Session Ⅳ-2
Recent progress in basic and clinical research of liver cancer stem
cells
- Taro Yamashita
Kanazawa University Hospital, Japan
Session Ⅳ-3
The phosphorylated retinoid X receptor-α promotes diethylnitrosamine-
induced hepatocarcinogenesis in mice through the activation of
β-catenin signaling pathway.
- Hiroyasu Sakai
Gifu University, Japan
Session Ⅳ-4
Stemness and heterogeneity in liver cancer
- Shinji Tanaka
Tokyo Medical and Dental University, Japan
Session Ⅳ-5
Drivers of cancer evolution in hepatocellular carcinoma: role in
biomarker discovery
- Augusto Villanueva
Icahn School of Medicine at Mount Sinai, USA
Session Ⅳ-6
Multiomics profiling identifies the pro-tumoral immune networks in the
steatotic tumor microenvironment in non-viral hepatocellular
carcinoma
- Takahiro Kodama
Osaka University, Japan
Session Ⅳ-7
Intratumoural immune heterogeneity as a hallmark of tumour evolution
in hepatocellular carcinoma
- Valerie Chew Suk Peng
SingHealth-DukeNUS Academic Medical Centre, Singapore
Session Ⅳ-8
Hepatocyte stellate cells in HCC lesions promote the growth of
hepatoma cells via autophagy dependent GDF15 secretion
- Hayato Hikita
Osaka University, Japan
Day 2: Sunday, October 3, 2021
[Room 1]
Workshop Ⅱ 9:00-10:30
The New Talent Workshop（Breakthrough basic researches in HCC for newly developed molecular and immune targeted therapies）
- Chair：
- Naoya Sakamoto
Hokkaido University, Japan - Koichiro Haruki
The Jikei University School of Medicine, Japan - Takeo Toshima
Kyushu University Beppu Hospital, Japan
Workshop Ⅱ-1
Molecular characteristics and the effectiveness of the combination
therapy of immune checkpoint inhibitor and angiogenesis inhibitor in
aggressive subtype hepatocellular carcinoma
- Tomohiko Taniai
Tokyo Medical and Dental University, Japan
Workshop Ⅱ-2
Novel anti-angiogenic therapy using tumor endothelial cell-specific
microRNA in hepatocellular carcinoma
- Hideki Iwamoto
Kurume University, Japan
Workshop Ⅱ-3
Leukotrienes Derived from Tumor-Infiltrating Macrophages Enhance
the Progression of Hepatocellular Carcinoma
- Takuto Nosaka
University of Fukui, Japan
Workshop Ⅱ-4
Phenotypic characterization by single-cell mass cytometry of human
intrahepatic and peripheral NK cells in patients with hepatocellular
carcinoma
- Sachiyo Yoshio
National Center for Global Health and Medicine, Japan
Invited Lecture Ⅰ10:35-11:35
New Treatment Paradigm for Intermediate/ Advanced Stage HCC
- Chair：
- Kiwamu Okita
Shunan Memorial Hospital, Japan
Invited Lecuture Ⅰ-1
- Masatoshi Kudo
Kindai University, Japan
Symposium Ⅱ 14:10-17:10
Current treatment of HCC; Asia, Europe and USA
- Chair：
- Masatoshi Kudo
Kindai University, Japan - Naoya Kato
Chiba University, Japan - Peter R. Galle
University Medical Center Mainz, Germany
Symposium Ⅱ-1
Current systemic therapy and treatment strategy for advanced HCC
in Europe
- Peter R. Galle
University Medical Center Mainz, Germany
Symposium Ⅱ-2
Downstaging Locally Advanced HCC to curative resection: the
experience of the National Cancer Center Singapore and the Singapore
General Hospital with selective internal radiation therapy (SIRT)
- Pierce Kah Hoe Chow
Duke-NUS Medical School, Singapore
Symposium Ⅱ-3
Current treatment selection for primary liver cancer in Japan:
Real-world data from a nationwide registry based on multiple
hospitalizations
- Kazuya Okushin
The University of Tokyo, Japan
Symposium Ⅱ-4
Transition of molecular target agent therapy and evolution of its
impact in advanced hepatocellular carcinoma: A multicenter，
survival retrospective study
- Kazufumi Kobayashi
Chiba University, Japan
Symposium Ⅱ-5
Difference of clinical guidelines for hepatocellular carcinoma
between Japan and overseas; A focus on hepatic arterial
infusion chemotherapy
- Kazuomi Ueshima
Kindai University, Japan
Symposium Ⅱ-6
Molecular and immune therapies for HCC
- Josep M Llovet
Icahn School of Medicine at Mount Sinai, USA
[Room 2]
Session Ⅴ 9:00-10:30
New positioning of RFA/TACE/HAIC/TKI in immunotherapy era
- Chair：
- Hiroko Iijima
Hyogo College of Medicine, Japan - Ryosuke Tateishi
The University of Tokyo Hospital, Japan - Andrew X. Zhu
Massachusetts General Hospital, USA - Kwang-Hyub Han
National Evidence-based Healthcare Collaborating Agency, Korea
Session Ⅴ-1
The efficacy and safety of sequential therapy with lenvatinib and
transarterial chemoembolization for unresectable hepatocellular
carcinoma.
- Tatsuya Kakegawa
Musashino Red Cross Hospital, Japan
Session Ⅴ-2
Role and the prognostic factors of hepatic arterial infusion
chemotherapy `New FP` for advanced HCC beyond up to 7 criteria
- Takashi Niizeki
Kurume University, Japan
Session Ⅴ-3
The role of tyrosine kinase inhibitor in the era of immune therapy for
patients with hepatocellular
- Do Young Kim
Yonsei University, Korea
Session Ⅴ-4
Locoregional therapies in the era of molecular and immune treatments
for hepatocellular carcinoma
- Riccardo Lencioni
University of Pisa, Italy
Invited Lecture Ⅱ10:35-11:35
The Global Impact of NAFLD: A 2021 Update
- Chair：
- Kazuhiko Koike
Kanto Centoral Hospital, Japan
Invited Lecuture Ⅱ-1
- Zobair M Younossi
Inova Medicine Services, USA
Session Ⅵ 14:10-15:40
Forefront diagnosis and treatment of HCC (including AI and liver regenerative treatment)
- Chair：
- Michiie Sakamoto
Keio University, Japan - Satoshi Mochida
Saitama Medical University, Japan - Kengo Yoshimitsu
Fukuoka University, Japan
Session Ⅵ-1
Liquid biopsy based on sensitive methylated SEPT9 as a prognostic
marker in hepatocellular carcinoma patients treated with molecular
targeted agents
- Issei Saeki
Yamaguchi University, Japan
Session Ⅵ-2
Genetic analyses of primary liver cancer cell lines using whole-exome
sequencing and fusion gene analysis
- Jun Akiba
Kurume University Hospital, Japan
Session Ⅵ-3
Role of alteration of oncogenic pathways on the
immunological microenvironment of hepatocellular carcinoma and its
clinical implications
- Naoshi Nishida
Kindai University, Japan
Session Ⅵ-4
Advanced CT and MRI for Hepatocellular Carcinoma
- Takamichi Murakami
Kobe University, Japan
Session Ⅶ 15:40-17:10
Viral Hepatitis/Fibrosis/NASH
- Chair：
- Norifumi Kawada
Osaka City University, Japan - Atsushi Nakajima
Yokohama City University, Japan - Hitoshi Yoshiji
Nara Medical University, Japan
Session Ⅶ-1
The incidence rates of complications in Japanese patients with
histopathologically-confirmed NAFLD - Expectations for suppression of
cardiovascular diseases and liver-related events with SGLT2 inhibitor
in NAFLD complicated by diabetes mellitus
- Norio Akuta
Toranomon Hospital, Japan
Session Ⅶ-2
Bezafibrate treatment is associated with reduced risk for development
of hepatocellular carcinoma in a large-scale Japanese cohort of PBC
patients
- Kosuke Matsumoto
Teikyo University, Japan
Session Ⅶ-3
Recent progress and future perspective on antiviral therapy to prevent
HBV-related HCC
- Sang Hoon Ahn
Yonsei University, South Korea
Session Ⅶ-4
Hepatocellular carcinoma in SVR achieved CHC patients after DAA
treatment
- Wakita Takaji
National Institute of Infectious Diseases, Japan